### Analysis:

The earnings call for Acceleron Pharmaceuticals highlighted a number of key points that are likely to impact the stock price over the next 1-2 weeks. Here are the main takeaways:

1. **Regulatory Filings and Approvals**: The company has received positive regulatory filings for luspatercept, which is a significant milestone. The FDA granted priority review for beta-thalassemia and set a target action date for April 4, 2020. This positive news is likely to boost investor sentiment.

2. **Clinical Trial Results**: The company expects top-line results from several ongoing clinical trials, including the FSHD and CMT trials for ACE-083, and the PULSAR trial for sotatercept. These results are crucial as they will determine the potential for future approvals and market expansion.

3. **Financial Performance**: The company reported a net loss for the second quarter, but this was expected given the investment in research and development. The cash position is strong, with $500.9 million as of June 30, 2019, which includes milestone payments for luspatercept.

4. **Collaboration and Co-Promotion**: The company is collaborating with Celgene and Bristol-Myers Squibb for luspatercept, which will help drive commercial success. The co-promotion strategy ensures a dedicated team and coordination efforts to maximize market penetration.

5. **Pipeline Expansion**: Acceleron is actively expanding its pipeline, including exploring new indications for luspatercept and other therapeutic areas. This suggests a long-term growth strategy.

### Conclusion:

The earnings call provided a mix of positive and neutral information. The regulatory filings and expected clinical trial results offer significant upside potential, while the financial performance and cash position are stable. Given the strong pipeline and positive regulatory momentum, investors are likely to view this as a positive development. The stock is expected to rally in the short term.

**Rating: 1**